MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..
  


CellCept

Company: Roche
Approval Status: Approved February 1998
Treatment for: prevention of organ rejection inpatients undergoing heart transplants
Areas: Cardiovascular / Cardiology; Diabetes / Endocrinology; Immune System

| General Information | Side Effects |


General Information

CellCept when used in combination with cyclosporine and corticosteroids has been approved for the prevention of organ rejection inpatients undergoing heart transplants. CellCept has previously been approved for the prevention of organ rejection in kidney-transplant patients.


Side Effects

The principal adverse reactions associated with the administration of Cell Cept include diarrhea, leukopenia (reduction of white blood cells), sepsis, and vomiting, and there is evidence of a higher frequency of certain types of infections.




< back to top

CellCept Drug Information

The Cellcept drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.





MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2014 All rights reserved.